The global Potassium Dehydroandrographolide Succinate Injection market size is predicted to grow from US$ 32.8 million in 2025 to US$ 46 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.

Potassium Dehydroandrographolide Succinate Injection is a traditional Chinese medicine preparation. Its main ingredient is chlorogenic acid, an effective ingredient extracted from honeysuckle, a plant of the Caprifoliaceae family. After chemical modification, it is obtained as a succinylated derivative, namely andrographolide succinate. This drug has pharmacological effects such as clearing away heat and detoxification, anti-inflammatory, antibacterial and antiviral. It is mainly used clinically to treat symptoms such as fever, sore throat, cough, etc. caused by exogenous wind-heat, as well as diseases such as acute tonsillitis and upper respiratory tract infection.

United States market for Potassium Dehydroandrographolide Succinate Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Potassium Dehydroandrographolide Succinate Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Potassium Dehydroandrographolide Succinate Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Potassium Dehydroandrographolide Succinate Injection players cover Sichuan Meida Kanghuakang Pharmaceutical Co., Ltd., Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., Sinopharm Group Yibin Pharmaceutical Co., Ltd., Harbin Pharmaceutical Group Sanjin Pharmaceutical Co., Ltd., Xian Lijun Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

Infinity Market Research newest research report, the ?Potassium Dehydroandrographolide Succinate Injection Industry Forecast? looks at past sales and reviews total world Potassium Dehydroandrographolide Succinate Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Potassium Dehydroandrographolide Succinate Injection sales for 2025 through 2031. With Potassium Dehydroandrographolide Succinate Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Potassium Dehydroandrographolide Succinate Injection industry.

This Insight Report provides a comprehensive analysis of the global Potassium Dehydroandrographolide Succinate Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Potassium Dehydroandrographolide Succinate Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Potassium Dehydroandrographolide Succinate Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Potassium Dehydroandrographolide Succinate Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Potassium Dehydroandrographolide Succinate Injection.

This report presents a comprehensive overview, market shares, and growth opportunities of Potassium Dehydroandrographolide Succinate Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    10ml:0.2g
    5ml:0.1g

Segmentation by Application:

    Hospital
    Clinic
    Other

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Sichuan Meida Kanghuakang Pharmaceutical Co., Ltd.
    Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
    Sinopharm Group Yibin Pharmaceutical Co., Ltd.
    Harbin Pharmaceutical Group Sanjin Pharmaceutical Co., Ltd.
    Xian Lijun Pharmaceutical Co., Ltd.
    Henan Furen Huaiqingtang Pharmaceutical Co., Ltd.
    Chengdu Tiantaishan Pharmaceutical Co., Ltd.
    Changshu Leiyunshang Pharmaceutical Co., Ltd.
    Chengdu Haitong Pharmaceutical Co., Ltd.
    Sucheng Pharmaceutical Co., Ltd.
    Chongqing Laimi Pharmaceutical Co., Ltd.
    Jilin Aodong Taonan Pharmaceutical Co., Ltd.
    Liaoning Keji Pharmaceutical Co., Ltd.
    Heilongjiang Ruige Pharmaceutical Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Potassium Dehydroandrographolide Succinate Injection market?
What factors are driving Potassium Dehydroandrographolide Succinate Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Potassium Dehydroandrographolide Succinate Injection market opportunities vary by end market size?
How does Potassium Dehydroandrographolide Succinate Injection break out by Type, by Application?